The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists
Open accessAbstract
Insulin resistance is a characteristic feature of most patients with type 2 diabetes mellitus and is almost a universal finding in type 2 diabetic patients who are overweight (1–3). The presence of insulin resistance leads to increased β-cell insulin secretion with compensatory hyperinsulinemia (1–3). As long as the hyperinsulinemia is adequate to overcome the insulin resistance, glucose tolerance remains normal. In patients destined to develop type 2 diabetes, the β-cell compensatory response declines, and relative, or absolute, insulin insufficiency develops. At this point, insulin secretion cannot keep pace with the underlying insulin resistance, and glucose intolerance and eventually frank type 2 diabetes occur. Based on these observations it is evident that, except for very unusual patients, type 2 diabetes only develops in the context of insulin resistance plus β cell dysfunction. Although there is still some debate as to whether the insulin resistance or the β-cell defect comes first, most epidemiologic studies have indicated that in the early, prediabetic state, insulin resistance is the antecedent abnormality (4, 5).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
The coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Barroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
Cited by
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,225
Type 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662
Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2094 · Cited by 1,659
Pajvani, U. B., Hawkins, M., Combs, T. P., Rajala, M. W., Doebber, T., Berger, J. P., Wagner, J. A., Wu, M., Knopps, A., Xiang, A. H., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311113200 · Cited by 1,163
Self-citationDiabetes and mitochondrial function: Role of hyperglycemia and oxidative stress
Rolo, A. P., & Palmeira, C. M. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.01.003 · Cited by 1,007
“In this respect, PPARγ appears to be of promising pharmacological interest since it was identified as the target of TZDs used in the treatment of non-insulin-dependent diabetes mellitus (Olefsky, 2000; Ram, 2003).”
BackgroundHe, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536828100 · Cited by 976
Self-citationAdiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome
TRUJILLO, M. E., & SCHERER, P. E. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01426.x · Cited by 769
Yu, J. G., Javorschi, S., Hevener, A. L., Kruszynska, Y. T., Norman, R. A., Sinha, M., & Olefsky, J. M. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2968 · Cited by 725
Self-citationGavrilova, O., Haluzik, M., Matsusue, K., Cutson, J. J., Johnson, L., Dietz, K. R., Nicol, C. J., Vinson, C., Gonzalez, F. J., & Reitman, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300043200 · Cited by 707
Bays, H., Mandarino, L., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030723 · Cited by 664
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Role of leptin and adiponectin in insulin resistance
Yadav, A., Kataria, M. A., Saini, V., & Yadav, A. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.12.007 · Cited by 637
Yu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., Rao, M. S., Gonzalez, F. J., & Reddy, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210062200 · Cited by 619
Savage, D. B., Sewter, C. P., Klenk, E. S., Segal, D. G., Vidal-Puig, A., Considine, R. V., & O’Rahilly, S. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2199 · Cited by 572
Marx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Diabetes mellitus and genetically programmed defects in β-cell function
Bell, G. I., & Polonsky, K. S. (2001) · Nature · doi:10.1038/414788a · Cited by 475
Insulin resistance associated to obesity: the link TNF-alpha
Nieto-Vazquez, I., Fernández-Veledo, S., Krämer, D. K., Vila-Bedmar, R., Garcia-Guerra, L., & Lorenzo, M. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802181047 · Cited by 471
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Lecka-Czernik, B., Moerman, E. J., Grant, D. F., Lehmann, J. M., Manolagas, S. C., & Jilka, R. L. (2002) · Endocrinology · doi:10.1210/endo.143.6.8834 · Cited by 441
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
An Integrated View of Immunometabolism
Lee, Y. S., Wollam, J., & Olefsky, J. M. (2018) · Cell · doi:10.1016/j.cell.2017.12.025 · Cited by 436
Self-citationChlorinated Persistent Organic Pollutants, Obesity, and Type 2 Diabetes
Lee, D.-H., Porta, M., Jacobs, D. R., & Vandenberg, L. N. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1084 · Cited by 420
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Morán‐Salvador, E., López‐Parra, M., García‐Alonso, V., Titos, E., Martínez‐Clemente, M., González‐Périz, A., López‐Vicario, C., Barak, Y., Arroyo, V., & Clària, J. (2011) · The FASEB Journal · doi:10.1096/fj.10-173716 · Cited by 389
Nagaev, I., & Smith, U. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5173 · Cited by 380
Natali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
PPARs: diverse regulators in energy metabolism and metabolic diseases
Wang, Y.-X. (2010) · Cell Research · doi:10.1038/cr.2010.13 · Cited by 366
Initial management of glycemia in type 2 diabetes mellitus
Nathan, D. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp021106 · Cited by 359
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism
Stumvoll, M., & Häring, H. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2341 · Cited by 332
The secretory function of adipocytes in the physiology of white adipose tissue
Wang, P., Mariman, E., Renes, J., & Keijer, J. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21386 · Cited by 318
Pathophysiological implications of insulin resistance on vascular endothelial function
Wheatcroft, S. B., Williams, I. L., Shah, A. M., & Kearney, M. T. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00869.x · Cited by 306
Tamori, Y., Masugi, J., Nishino, N., & Kasuga, M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2045 · Cited by 294
Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285
Satoh, N., Ogawa, Y., Usui, T., Tagami, T., Kono, S., Uesugi, H., Sugiyama, H., Sugawara, A., Yamada, K., Shimatsu, A., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.9.2493 · Cited by 289
Lessons from the glitazones: a story of drug development
Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 287
Mechanisms of Insulin Resistance in Humans and Possible Links With Inflammation
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2005) · Hypertension · doi:10.1161/01.hyp.0000163475.04421.e4 · Cited by 286
Matsubara, T., Mita, A., Minami, K., Hosooka, T., Kitazawa, S., Takahashi, K., Tamori, Y., Yokoi, N., Watanabe, M., Matsuo, E.-I., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.002 · Cited by 286
McTernan, P. G., Fisher, F. M., Valsamakis, G., Chetty, R., Harte, A., McTernan, C. L., Clark, P. M. S., Smith, S. A., Barnett, A. H., & Kumar, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030898 · Cited by 280
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats
Satoh, H., Nguyen, M. T., Miles, P. D. G., Imamura, T., Usui, I., & Olefsky, J. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420785 · Cited by 268
Self-citationHwang, J., Kleinhenz, D. J., Lassègue, B., Griendling, K. K., Dikalov, S., & Hart, C. M. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00474.2004 · Cited by 268
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
Dysfunctional fat cells, lipotoxicity and type 2 diabetes
Defronzo, R. A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00389.x · Cited by 236
Sheng, X., Zhang, Y., Gong, Z., Huang, C., & Zang, Y. Q. (2008) · PPAR Research · doi:10.1155/2008/581348 · Cited by 203
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
Sidell, R. J., Cole, M. A., Draper, N. J., Desrois, M., Buckingham, R. E., & Clarke, K. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1110 · Cited by 165
Arlt, W., Auchus, R. J., & Miller, W. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100040200 · Cited by 157
Carley, A. N., Semeniuk, L. M., Shimoni, Y., Aasum, E., Larsen, T. S., Berger, J. P., & Severson, D. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00329.2003 · Cited by 94
Sung, C. K., She, H., Xiong, S., & Tsukamoto, H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00411.2003 · Cited by 63
Tejerina, S., De Pauw, A., Vankoningsloo, S., Houbion, A., Renard, P., De Longueville, F., Raes, M., & Arnould, T. (2009) · Journal of Cell Science · doi:10.1242/jcs.027508 · Cited by 46
Goya, K., Sumitani, S., Otsuki, M., Xu, X., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., & Kasayama, S. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.003 · Cited by 43
Heshmati, J., Sepidarkish, M., Morvaridzadeh, M., Farsi, F., Tripathi, N., Razavi, M., & Rezaeinejad, M. (2021) · Journal of Food Biochemistry · doi:10.1111/jfbc.13543 · Cited by 40
Metadata
- Authors
- Olefsky, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-08-15
- Volume
- 106
- Issue
- 4
- Pages
- 467-472
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1983128420
- Cited by
- 537
- References
- 48
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.